Journal: Scientific Reports

Article Title: Structure-Guided Design of a Fluorescent Probe for the Visualization of FtsZ in Clinically Important Gram-Positive and Gram-Negative Bacterial Pathogens

doi: 10.1038/s41598-019-56557-x

Figure Lengend Snippet: FtsZ visualization in the Gram-positive bacterial pathogens S. aureus NRS705 ( a , b ), E. faecalis ATCC 29212 ( c , d ), E. faecium ATCC 19434 ( e , f ), S. pyogenes ATCC 19615 ( g , h ), S. agalactiae ATCC 12386 ( i , j ), and S. pneumoniae ATCC 49619 ( k , l ). Differential interference contrast (DIC) and fluorescence micrographs of the indicated bacterial cells treated for 5 minutes with 1 µg/mL BOFP just prior to visualization. The arrows in panels (b,d,f,h,j,l) highlight representative FtsZ Z-rings at midcell labeled by BOFP .

Article Snippet: S. aureus NRS705 (a USA100 MRSA strain isolated from the blood of a 14-day-old male in New York) was provided by the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) for distribution by BEI Resources, NIAID, NIH.

Techniques: Fluorescence, Labeling

Journal: Scientific Reports

Article Title: Structure-Guided Design of a Fluorescent Probe for the Visualization of FtsZ in Clinically Important Gram-Positive and Gram-Negative Bacterial Pathogens

doi: 10.1038/s41598-019-56557-x

Figure Lengend Snippet: Visualization of the impact of treatment with 1 on FtsZ localization in S. aureus NRS705, E. coli N43, and K. pneumoniae ATCC 10031. Differential interference contrast (DIC) and fluorescence micrographs of the indicated bacterial cells treated for 3 hours with either DMSO vehicle ( a – f ) or 1 ( g – l ) at 4× MIC (1 µg/mL for S. aureus and 4 µg/mL for E. coli and K. pneumoniae ). Just prior to visualization, cells were labeled for 5 minutes with 1 µg/mL BOFP in the absence (for S. aureus ) or presence of pentamidine isethionate (at 0.875 mg/mL for E. coli and 3.5 mg/mL for K. pneumoniae ). The arrows in panels (b,d,f) highlight representative FtsZ Z-rings at midcell labeled by BOFP .

Article Snippet: S. aureus NRS705 (a USA100 MRSA strain isolated from the blood of a 14-day-old male in New York) was provided by the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) for distribution by BEI Resources, NIAID, NIH.

Techniques: Fluorescence, Labeling

Journal: Future Science OA

Article Title: A phytotherapeutic approach to hinder the resistance against clindamycin by MRSA: in vitro and in silico studies

doi: 10.1080/20565623.2025.2458438

Figure Lengend Snippet: The computed MICs of plant essential oils against the tested MRSA strain and MRSA human clinical isolate are expressed as a volume/volume percentage (% v/v) of oil in MHB with the addition of 0.5% Tween 80 ± standard deviation.

Article Snippet: MRSA (ATCC 43300 strain and MRSA human clinical isolate obtained from sputum sample isolated on Blood Agar Base (HiMedia, India) supplemented with 25 mL of filter sterilized sheep blood (Thermo Scientific, UK)) were grown on Mueller-Hinton agar (MHB) and incubated (37 °C, 24 h) for later usage.

Techniques: Inhibition

Journal: Future Science OA

Article Title: A phytotherapeutic approach to hinder the resistance against clindamycin by MRSA: in vitro and in silico studies

doi: 10.1080/20565623.2025.2458438

Figure Lengend Snippet: A) Antimicrobial activity of the binary formulas, oil-clindamycin against MRSA ATCC 43300.

Article Snippet: MRSA (ATCC 43300 strain and MRSA human clinical isolate obtained from sputum sample isolated on Blood Agar Base (HiMedia, India) supplemented with 25 mL of filter sterilized sheep blood (Thermo Scientific, UK)) were grown on Mueller-Hinton agar (MHB) and incubated (37 °C, 24 h) for later usage.

Techniques: Activity Assay